Received Jun 18, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 52YC5 | — |
on June 9, 2026 only the liquid portion of the Penmenvy vaccine was administered to a patient; on June 9, 2026 only the liquid portion of the Penmenvy vaccine was administered to a patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 17-year-old female patient who received Men ABCWY NVS (Penmenvy) suspension for injection in pre-filled syringe (batch number 52YC5 with expiry date 23-SEP-2027) for prophylaxis. On 09-JUN-2026, the patient received Penmenvy. On 09-JUN-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate preparation of medication (Verbatim: on June 9, 2026 only the liquid portion of the Penmenvy vaccine was administered to a patient) and inappropriate dose of vaccine administered (Verbatim: on June 9, 2026 only the liquid portion of the Penmenvy vaccine was administered to a patient). This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.